Naloxone formulations for sublingual and/or buccal administration
Liquid, gel, and semi-solid compositions containing naloxone base, or isomers or derivatives thereof, with one or more non-aqueous solvents, and optional viscosity adjusting agents, are provided. Methods of treating an individual exhibiting symptoms of respiratory depression associated with known or suspected opioid overdose including administering a liquid, gel, or semi-solid formulation containing a solution of naloxone base, or an isomer or a derivative thereof, in one or more non-aqueous solvents, are also provided.
1. A liquid, gel or semi-solid pharmaceutical composition comprising:
from about 1% to about 25% of naloxone base, or an isomer or a derivative thereof, by the total mass of the composition; and
from about 50% to about 99% of one or more non-aqueous solvents selected from the group consisting of oleic acid, liquid polyethylene glycol, propylene glycol, and ethanol, or mixtures thereof, by the total mass of the composition;
wherein the composition is substantially free of water; and
wherein the naloxone base, or isomer or derivative thereof, is completely and homogeneously dissolved in the one or more non-aqueous solvents.
2. The pharmaceutical composition of claim 1 , further comprising from about 1% to about 25% one or more viscosity adjusting agents selected from the group consisting of calcium silicate, acacia, carbomers, carboxymethylcellulose sodium, silicon dioxide, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose, methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol or mixtures thereof, by the total mass of the composition.
3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is for sublingual or buccal delivery.
4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a liquid pharmaceutical composition.
5. The pharmaceutical composition of claim 1 , comprising the naloxone base, or isomer or derivative thereof, in an amount of from about 1 mg to about 20 mg; and the one or more non-aqueous solvents in a combined amount of from about 50 mg to about 500 mg.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition provides a plasma concentration of naloxone of at least about 1 ng/mL in less than about 15 minutes following sublingual or buccal administration of the pharmaceutical composition to an individual.
7. The pharmaceutical composition of claim 6 , wherein the individual is exhibiting symptoms of respiratory depression associated with known or suspected opioid overdose.
8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is configured for sublingual or buccal administration to an individual from a single unit dosage form container selected from the group consisting of a spray dispenser, an oral syringe, or a blow-fill-seal unit dose dispenser.
9. The pharmaceutical composition of claim 8 , wherein the individual is exhibiting symptoms of respiratory depression associated with known or suspected opioid overdose.